2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

401. Blood Transfusion: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Serologic Tests, Blood Banking, Treatment Considerations, Supportive Care, Biological Therapies, Transfusion, Women’s Health, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Bleeding and Clotting, Bleeding Disorders, Thrombocytopenias, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Immunology, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

3119 Platelet transfusion alters the systemic cytokine response and lung leukocyte populations in a neonatal model of LPS-induced thrombocytopenia

Mifra Faiz, Amalia El Nems2, Jesselin Romero Escobar3, Erin Soule-Albridge4, Henry A Feldman5, Martha Sola-Visner, MD6, Patricia Davenport, MD7
1 Boston Children's Hospital, Boston, Massachusetts, United States
2 Boston Children's Hospital, Boston, Massachusetts, United States
3 Boston Children's Hospital, Boston, Massachusetts, United States
4 Boston Children's Hospital, Boston, Massachusetts, United States
5 Boston Children's Hospital, Boston, Massachusetts, United States
6 Boston Children's Hospital, Boston, Massachusetts, United States
7 Boston Children's Hospital, Boston, Massachusetts, United States

Background:  Preterm neonates frequently receive platelet (PLT) transfusions, due to their high incidence of both thrombocytopenia and bleeding. However, a large, randomized trial found a significantly higher incidence of death and/or major bleeding and of chronic lung disease among preterm neonates transfused at a higher compared to a lower PLT count threshold. Work from our group and others suggests that the mechanisms underlying these findings may be related to the functional developmental differences that exist between adult and neonatal PLTs, and to the “developmental mismatch” that occurs when relatively hyper-active adult PLTs are transfused into a neonate. In addition to their hemostatic functions, it is now clear that PLTs are also key modulators of immune and inflammatory responses, and recent studies have uncovered significant differences in the immune program of neonatal compared to adult platelets in both mice and humans. Based on these observations, we hypothesized that transfusion of adult PLTs into neonatal mice with lipopolysaccharide (LPS)-induced thrombocytopenia would enhance the systemic inflammatory response and would affect the immune cell populations in the neonatal lung.  

Methods: To test this hypothesis, we IP injected post-natal day 10 (P10) C57BL/6 pups with LPS at a sub-lethal dose (1µg/g), which induced mild weight loss, thrombocytopenia, and leukopenia followed by leukocytosis. Two hours after LPS injection, pups were transfused with either washed PLTs from adult C57BL/6 mice or with Tyrodes (TY) buffer (controls). Pups were then euthanized 4- or 18- hours after transfusion for terminal blood draw and quantification of plasma cytokines by Luminex. A separate set of pups with the same experimental conditions was euthanized 24- hours post-transfusion for lung perfusion followed by characterization of the lung CD45+ cell populations by spectral flow cytometry.

Results:  PLT-transfused pups exhibited significantly greater weight loss compared to TY controls (p<0.01), suggesting more severe illness. At the 4h timepoint, PLT transfused pups had significantly higher levels of leukemia inhibitory factor (LIF, a member of the IL-6 family) compared to TY controls (356 pg/mL vs. 174 pg/mL, p<0.01) and both groups had extremely high levels of IL-6 (off the standard curve). By 18h, most cytokines had decreased to near-normal levels in TY pups, while IL-6 and IL-10 remained elevated in PLT transfused pups. Comparison of the IL-6 to IL-10 ratio in PLT vs TY transfused mice showed that IL-6 levels were 2.3 times higher for any given IL-10 level in pups who received a PLT transfusion compared to TY, suggesting an overall more pro-inflammatory response.

In spectral flow cytometry analysis of lung leukocyte populations 24h after transfusion (500,000 cells collected), PLT transfused pups exhibited significantly higher percentages of CD45+ cells (29.54.1% vs 9.20.70% live cells, p=0.01), with significantly larger numbers of total lung B-cells (13,723±3,400 vs. 3,354±600, p<0.01), CD4+ T-cells (8,277±1,470 vs. 1,776±193, p<0.01), tissue-resident macrophages (11,330±951 vs. 2,937±845, p<0.01), and alveolar macrophages (6,850±820 vs. 1,557±456, p<0.01) compared to TY pups. PLT transfused pups also had an increased population of CD86+ alveolar macrophages (1,374±416 cells vs. 129.0±101cells, p<0.01), indicating a more pro-inflammatory phenotype.

Conclusions: Taken together our data indicates that transfusion of adult PLTs into newborn mice with thrombocytopenia associated with sterile inflammation alters both the systemic cytokine response and the lung-specific innate and adaptive immune responses, skewing all towards a more pro-inflammatory state that potentially could contribute to poorer neonatal outcomes.

Mifra Faiz: No relevant conflicts of interest to declare.